AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida.
| Revenue (Most Recent Fiscal Year) | $0.09M |
| Net Income (Most Recent Fiscal Year) | $-13.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 55.09 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -15861.36% |
| Net Margin (Trailing 12 Months) | -15861.36% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -209.50% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.44 |
| Earnings per Share (Most Recent Fiscal Year) | $-7.01 |
| Diluted Earnings per Share (Trailing 12 Months) | $-10.69 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 8.15M |
| Free Float | 3.27M |
| Market Capitalization | $4.85M |
| Average Volume (Last 20 Days) | 9.91M |
| Beta (Past 60 Months) | 1.36 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.04% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.02% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |